Alterola Biotech Inc. (OTCMKTS:ABTI)
NEVADA, USA, September 15, 2023 /
EINPresswire.com/ --
Alterola Biotech Inc. (
https://alterola-abti.com/). (OTC PINK: ABTI) ("Alterola"), a pharmaceutical company developing cannabinoid and cannabinoid-like medicines and active pharmaceutical ingredients (APls), today announces it has signed an agreement to re-sell the assets it initially acquired from C2 Wellness Corporation in November 2021 back to the company.
As part of the agreement, C2 Wellness Corporation have agreed to re-purchase the assets in return for 30,019,493 ABTI shares. Such shares will be returned to Alterola’s treasury within 21 days of the date of the Agreement. In addition, Alterola will return the assets and associated intellectual property to C2 Wellness Corporation within the 21-day timeframe.
Timothy Rogers, Executive Chairman of Alterola Biotech Inc. said “We are pleased to have come to an amicable agreement whereby the assets return to C2 Wellness Corporation, who have the expertise and capability to develop them. We wish C2 Wellness Corporation the very best with their future development of the technologies and look forward to the possibility of exploring other potential opportunities for joint ventures and collaborations in the future."
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as "expect,"
"anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate,"
"potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission {the "SEC") on October 19, 2021 and declared effective October 29, 2021, and the Quarterly Report on Form 10-Q filed with the SEC on August 15, 2023, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the company's results is included in the Company's SEC filings, which may be obtained by visiting the SEC's website at
www.sec.gov {httP-:ll
www.sec.gov).
About Alterola Biotech
Alterola Biotech Inc. is a pharmaceutical company developing cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients {APls) and targeting European novel food approval of cannabinoidbased, cannabinoid-like and non-cannabinoid ingredients and products.
Tim Rogers
Alterola Biotech Inc.
Tel. No.: +44 151 607 9477
Email: info@alterolabio.com
Timothy Rogers
Alterola Biotech Inc.
+44 151 601 9477
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn